GlassScriptPhysician profile
Michael Luther
NPI 1013180132
$5,511.91
in general payments reported to CMS, 2019-2025
35 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $1,869 · 2021: $1,407 · 2022: $71.96 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,034.45 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $480.13 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $408.14 | 2019-2021 | |
| Amarin Pharma, INC. | $383.81 | 2019-2021 | |
| Abbvie INC. | $305.69 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.08 | 2019-2025 | Xifaxan |
| Pfizer INC. | $279.41 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.09 | 2019-2021 | |
| Amgen INC. | $239.60 | 2019-2025 | Repatha |
| Allergan, INC. | $205.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $192.13 | 2019-2021 | |
| Qiagen, LLC | $143.21 | 2019 | |
| Glaxosmithkline, LLC. | $140.27 | 2020-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $136.12 | 2019-2021 | |
| Astellas Pharma US INC | $131.07 | 2019-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $119.18 | 2019-2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $113.93 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $90.23 | 2019 | |
| Eisai INC. | $79.36 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.58 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $49.54 | 2019 | |
| Esperion Therapeutics, INC. | $46.80 | 2021 | |
| Boston Scientific Corporation | $45.11 | 2022 | |
| Dexcom, INC. | $44.20 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $40.29 | 2019-2021 | |
| Genentech USA, INC. | $37.32 | 2020-2021 | |
| Janssen Biotech, INC. | $35.20 | 2019 | |
| Neurocrine Biosciences, INC. | $20.23 | 2025 | |
| Aimmune Therapeutics, INC. | $19.81 | 2025 | Zenpep |
| Sanofi-Aventis U.S. LLC | $17.75 | 2020 | |
| Exact Sciences Corporation | $16.61 | 2025 | The Cologuard Plus Collection Kit |
| Jazz Pharmaceuticals INC. | $15.14 | 2021 | |
| Currax Pharmaceuticals LLC | $13.91 | 2021 | |
| Organon LLC | $13.18 | 2025 | Nexplanon |
| Aytu Biopharma, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Luther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.